Connect your AI

Immunome IMNM Payments to Acquire in Process Research and Development

Payments to Acquire in Process Research and Development at other companies

ExelixisEXEL

——

Eli LillyLLY

——

Other financials

Income statement

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

Market cap$2.24B+323%

Enterprise value$1.66B+470%

P/S557.1×+509×

Profitability

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's payments to acquire in process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Immunome's payments to acquire in process research and development?: Immunome (IMNM) reported payments to acquire in process research and development of $9.01M in Q1 2026.
How has Immunome's payments to acquire in process research and development changed year-over-year?: Immunome's payments to acquire in process research and development increased by 44.3% year-over-year, from $6.25M to $9.01M.